Please login to the form below

Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic

Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’ approaches to combatting the disease and explore the importance of a de-centralized strategy that overcomes the stigma preventing patients from seeking treatment.

This year’s World Hepatitis Day theme, ‘Hepatitis Can’t Wait,’ stresses the urgency of testing and treating viral hepatitis, as well as removing the stigma surrounding the disease and providing support for patients.

Treatment for hepatitis C has evolved dramatically over the past decade. The introduction of direct-acting-antivirals has revolutionized the treatment landscape, leading the World Health Organization to set a global target to eliminate the disease as a public health problem by 2030.

Today hepatitis C is a curable disease. It takes just 8–12 weeks of oral therapy to successfully cure close to 100% of patients with chronic hepatitis C virus infection. Gone are the days of thrice-weekly injections, low cure rates, and a myriad of side effects. The treatment algorithm is far simpler, the therapies are less invasive, the side effects typically milder and much less frequent, and the time patients spend taking medication is far shorter. There is limited need for pre-treatment assessments, on-treatment monitoring, and post-treatment follow-up, making it much easier for patients to fit treatment into their daily lives.

Despite huge advances in the field, the burden of hepatitis C remains a significant public health problem. The World Health Organization (WHO) estimates that 71 million people globally have chronic hepatitis C.[1] Yet, 80% are unaware of their infection status, and a significant number of those will develop cirrhosis or liver cancer if not treated.[2] So, if a cure exists, why are so many people still infected with hepatitis C virus and suffering from the consequences of ongoing chronic infection and liver damage?

Download the full article to learn about: 

  • The approaches different countries are taking to eliminating hepatitis C
  • Successful strategies for engaging hard-to-reach patients
  • Why treating patients in active addiction is crucial for tackling the disease
  • Iceland case study

DOWNLOAD THE FULL ARTICLE HERE

31st August 2021

Share

Tags

Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

Address:
No. 3 Booths Park
Booths Hall
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom

Latest content on this profile

Future focus: 3 tools for launching fast in the face of uncertainty
Dan Twibell, Head of Commercial Strategy, Consulting at Fishawack Health, reveals 3 fundamental tools for lean biotechs approaching a rapid launch. He gives his advice on how to manage resources effectively and ensure the strategy remains agile in a changing market landscape.
Fishawack Health
Fishawack Health appoints new CEO, Jonathan Koch
Koch will draw on his exceptional experience leading global, customer-centered organizations of scale to build a sustainable future for Fishawack Health.
Fishawack Health
Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
Elizabeth Landon brings exceptional leadership from a career supporting and scaling people-based businesses in the professional services and non-profit sectors.
Fishawack Health
Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic
Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’ approaches to combatting the disease and explore the importance of a de-centralized strategy that overcomes the stigma preventing patients from seeking treatment.
Fishawack Health
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life science companies can cut through the noise to drive uptake of innovative therapies, including novel TYK2 inhibitors.
Fishawack Health
Healthcare tech: the driving force behind value-based care?
In 2020, healthcare technology investment went into overdrive. We speak to Sunny Kumar, Partner at GSR Ventures, to find out how COVID‑19 has transformed the industry and whether healthcare technology can bring us one step closer to a value-based model of care.
Fishawack Health